MedTrace Logo

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

NCT05872412 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2023-05-25

No results posted yet for this study

Summary

In this study, individuals with triple-negative breast cancer will receive either a platinum-based or non-platinum-based preoperative chemotherapy treatment. This study will help us identify which option is the most effective and safe.

Conditions

Interventions

DRUG

Doxorubicin

60 mg/m2 IV bolus on day 1 every three weeks for four cycles.

DRUG

Cyclophosphamide

600 mg/m2 IV over 1 hour on day 1 every three weeks for four cycles.

DRUG

Paclitaxel

80 mg/m2 IV over 1 hour weekly for 12 weeks

DRUG

Carboplatin

Area under the curve: 6 mg/ml/min, i.v. every 3 weeks for four cycles

Sponsors & Collaborators

  • Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

    lead OTHER

Principal Investigators

  • Mohammad J Shams, MBBS, MD · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-03-31
Completion
2024-04-30

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05872412 on ClinicalTrials.gov